When Reata Pharmaceuticals Inc. closed a $78 million Series G financing in July to push its chronic kidney disease drug bardoxolone to a new drug submission, CEO Warren Huff acknowledged that the Irving, Texas-based firm was looking for commercialization help outside the U.S. (See BioWorld Today, July 12, 2010.) (BioWorld Today) Read More
